Genzyme initiated patent infringement litigation against Impax in a US district court over kidney disease drug Renvela (sevelamer carbonate), Impax confirmed Monday. The California-based drugmaker said the lawsuit was filed after it notified Genzyme that its application to market a generic version of the treatment had been accepted by the FDA.

[ad]

The product had sales of about $40 million in the 12-month period ended February 2009.

Source: FirstWord

Popularity: 2% [?]